Celldex Therapeutics Inc. (CLDX)

Precedente Chiudi:

$36.26

Aprire:

$36.31

Volume 24 ore:

322.02K

Capitalizzazione di mercato:

$2.38B

Reddito:

$6.88M

Utile/perdita netta:

$-141.43M

Rapporto P/E:

-13.75

EPS:

-2.64

Flusso di cassa netto:

$-109.11M

1 W Prestazione:

-4.42%

1M Prestazione:

-11.55%

6M Prestazione:

+55.79%

1 anno Prestazione:

+12.28%

Intervallo 1D:

$35.65

$36.74

Portata 52W:

$22.11

$53.18

Celldex Therapeutics Inc. Stock (CLDX) Company Profile

Nome

Celldex Therapeutics Inc.

Settore

Healthcare (1191)

Industria

Biotechnology (688)

Telefono

908-200-7500

Indirizzo

Perryville III Building, Suite 220 53 Frontage Road, Hampton

Dipendente

192

Cinguettio

@search?q=celldex

Prossima data di guadagno

2024-05-02

Ultimi documenti SEC

CLDX's Discussions on Twitter

Celldex Therapeutics Inc. Stock (CLDX) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2023-12-20	Iniziato	TD Cowen	Outperform
2023-11-10	Aggiornamento	Wells Fargo	Underweight → Equal Weight
2023-08-22	Iniziato	Wells Fargo	Underweight
2021-09-17	Iniziato	Jefferies	Buy
2021-09-10	Iniziato	SVB Leerink	Outperform
2021-07-22	Iniziato	Guggenheim	Buy
2020-02-21	Iniziato	Cantor Fitzgerald	Overweight
2017-08-01	Ripresa	H.C. Wainwright	Buy
2016-11-07	Iniziato	Aegis Capital	Buy
2016-03-08	Downgrade	Jefferies	Buy → Hold
2016-03-07	Downgrade	Guggenheim	Buy → Neutral
2016-03-07	Downgrade	Leerink Partners	Outperform → Mkt Perform
2016-03-07	Downgrade	Wedbush	Outperform → Neutral
2016-03-01	Iniziato	H.C. Wainwright	Buy
2015-08-11	Reiterato	Brean Capital	Buy
2015-08-11	Reiterato	Oppenheimer	Outperform
2015-08-11	Reiterato	ROTH Capital	Buy
2015-06-02	Reiterato	WBB Securities	Strong Buy
2014-11-17	Reiterato	ROTH Capital	Buy
2014-03-04	Reiterato	Oppenheimer	Outperform
2013-07-08	Reiterato	Cantor Fitzgerald	Buy
2013-03-08	Reiterato	Cantor Fitzgerald	Buy
2013-02-26	Reiterato	Oppenheimer	Outperform
2013-01-10	Reiterato	Cantor Fitzgerald	Buy
2012-10-02	Reiterato	Oppenheimer	Outperform
2012-09-14	Reiterato	Cantor Fitzgerald	Buy

Mostra tutto

Celldex Therapeutics Inc. Borsa (CLDX) Ultime notizie

Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria

GlobeNewswire Inc.

Down -14.61% in 4 Weeks, Here's Why You Should You Buy the Dip in Celldex (CLDX)

Zacks Investment Research

All You Need to Know About Celldex (CLDX) Rating Upgrade to Buy

Zacks Investment Research

Down -17.39% in 4 Weeks, Here's Why You Should You Buy the Dip in Celldex (CLDX)

Zacks Investment Research

Does Celldex (CLDX) Have the Potential to Rally 71.82% as Wall Street Analysts Expect?

Zacks Investment Research

Celldex Therapeutics to Participate in the Leerink Partners Global Biopharma Conference

GlobeNewswire Inc.

Celldex Therapeutics Inc. Azioni (CLDX) Dati Finanziari

Celldex Therapeutics Inc. (CLDX) Reddito 2024

Celldex Therapeutics Inc. (CLDX) Reddito netto 2024

Celldex Therapeutics Inc. (CLDX) Flusso di cassa 2024

Celldex Therapeutics Inc. (CLDX) Utile per azione 2024